Literature DB >> 12558337

Epidemiology of measles, mumps and rubella in Italy.

G Gabutti1, M C Rota, S Salmaso, B M Bruzzone, A Bella, P Crovari.   

Abstract

A serosurvey for measles, mumps and rubella was conducted in Italy; incidence based on statutory notifications over the last three decades was also calculated. In Italy the diseases followed an endemic-epidemic pattern, with an incidence peak every 2-4 years, and had a limited reduction of incidence attributable to childhood immunization. Lower notification rates were observed in the Southern regions. This is possibly related to greater under notification in the South and is confirmed by our seroprevalence data. Incidence of measles and rubella and proportion of cases among young adults increased significantly in the three decades considered, but not for mumps. Serological data confirmed that these infections are still very frequent in Italy, without significant geographic variation in the country. In the age groups 2-4 and 5-9 years the percentage of individuals still susceptible to each virus was higher than 30%. The proportion of susceptible subjects older than 15 years was similar for the three infections (6.1, 11.7 and 8.8% for measles, mumps and rubella, respectively). The low vaccine coverage for rubella and measles in Italy has so far only partially affected the occurrence of the diseases. No impact of mumps vaccination is visible. The average number of deaths, for each disease, has decreased during the three study periods. Today the priority in Italy is to halt the progressive increase of the mean age of acquisition of the three infections, to eliminate differences in coverage among regions and to conform to European standards. This will be achieved through a combination of increasing MMR vaccine coverage before 2 years of age, implementing vaccination campaigns for low seroprevalence age groups, and/or introducing a second dose of MMR, depending on the level of current MMR coverage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12558337      PMCID: PMC2869916          DOI: 10.1017/s0950268802007677

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  12 in total

1.  A 5-year comparison of performance of sentinel and mandatory notification surveillance systems for measles in Switzerland.

Authors:  Jean-Luc Richard; Beatriz Vidondo; Mirjam Mäusezahl
Journal:  Eur J Epidemiol       Date:  2007-09-26       Impact factor: 8.082

2.  Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia.

Authors:  A Tischer; N Andrews; G Kafatos; A Nardone; G Berbers; I Davidkin; Y Aboudy; J Backhouse; C Barbara; K Bartha; B Bruckova; A Duks; A Griskevicius; L Hesketh; K Johansen; L Jones; O Kuersteiner; E Lupulescu; Z Mihneva; M Mrazova; F De Ory; K Prosenc; F Schneider; A Tsakris; M Smelhausova; R Vranckx; M Zarvou; E Miller
Journal:  Epidemiol Infect       Date:  2007-03-30       Impact factor: 2.451

3.  Attitude toward immunization and risk perception of measles, rubella, mumps, varicella, and pertussis in health care workers working in 6 hospitals of Florence, Italy 2011.

Authors:  Cristina Taddei; Vega Ceccherini; Giuditta Niccolai; Barbara Rita Porchia; Sara Boccalini; Miriam Levi; Emilia Tiscione; Maria Grazia Santini; Simonetta Baretti; Paolo Bonanni; Angela Bechini
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

4.  Deciphering the relative weights of demographic transition and vaccination in the decrease of measles incidence in Italy.

Authors:  Stefano Merler; Marco Ajelli
Journal:  Proc Biol Sci       Date:  2014-01-08       Impact factor: 5.349

5.  Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain: results of a cross-sectional study.

Authors:  A Domínguez; P Plans; J Costa; N Torner; N Cardenosa; J Batalla; A Plasencia; L Salleras
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-05       Impact factor: 3.267

6.  Rubella seroprofile of the Italian population: an 8-year comparison.

Authors:  M C Rota; A Bella; G Gabutti; C Giambi; A Filia; M Guido; A De Donno; P Crovari; M L Ciofi Degli Atti
Journal:  Epidemiol Infect       Date:  2006-11-01       Impact factor: 2.451

Review 7.  Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.

Authors:  Keri Wellington; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  The pre-vaccination regional epidemiological landscape of measles in Italy: contact patterns, effort needed for eradication, and comparison with other regions of Europe.

Authors:  Piero Manfredi; Eugene M Cleur; John R Williams; Stefania Salmaso; Marta Ciofi Degli Atti
Journal:  Popul Health Metr       Date:  2005-02-17

9.  The epidemiology of Varicella Zoster Virus infection in Italy.

Authors:  Giovanni Gabutti; Maria C Rota; Marcello Guido; Antonella De Donno; Antonino Bella; Marta L Ciofi degli Atti; Pietro Crovari
Journal:  BMC Public Health       Date:  2008-10-27       Impact factor: 3.295

Review 10.  Rubella antibody screening during pregnancy in an urban area of Northern Italy.

Authors:  Massimo De Paschale; Maria Teresa Manco; Alessia Paganini; Carlo Agrappi; Paola Mirri; Gabriella Cucchi; Barbara Saccani; Alberto Flores D'Arcais; Pierangelo Clerici
Journal:  Infect Dis Rep       Date:  2012-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.